SAN CARLOS, Calif. & LISBON, Portugal--March 7, 2024--CuraSen Therapeutics, Inc., a clinical-stage company developing small molecule therapies to treat neurodegenerative disease, announced that it will present additional positive Phase 2a...
Signase developed novel, small molecule inhibitors of a critical cell replication pathway to inhibit tumor growth. It was spun out of the M. D. Anderson Cancer Center. The company’s assets were acquired by Systems Medicine Inc. in 2005.
Signase
Houston, TX
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.